ç²¾ç¥å»å¦
ãã®2ã§ããä»æ¥åãä¸ããã®ãåå¦ç©è³ªéæçã¨ãããã¤ãã®é µç´ ã®éºä¼ååãæ±ã£ãè«æã§ããã¿ã¤ãã«ã¯ãCase-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR*1ã§ãããããåå¦ç©è³ªéæçã¯éºâ¦
ãã¤ç ã§äºå¹´éãã£ã¦ããã®ã§ããããªã¼ãã¹é£²ã¿å§ãã¦ãã絶好調ã§ãã3æ¥ãããã§å¹ãã¦ãã¾ãããä»é£²ãã§ãè¬ã¯ä»¥ä¸ã ãªã¼ãã¹ 200mgÃ2/day ã¸ã§ã¤ã¾ããã 20mgÃ2/day ã¢ã¢ããµã³ 50mgÃ1/day ãã¤ã¹ãªã¼ 5mgÃ1/ããã¾ã ä¸ç°ç³»ãSSRIã¨é£²ãã§ãã¦ããªâ¦
ãªããããæãã«å¹ãã¦ã¾ããã¾ã 400mg/dayãã飲ãã§ãªãã®ã«ã»ã»ã ãããªã«ã²ã©ãã£ãç æ°ããã£ã±ãããã¾ãã¾ããã ããã§ä¸æ¥ä¸è¡åã§ãããï¼ï¼ãªã¼ãã¹ããããï¼ï¼ èºé¬±ãããªããã©ç§ã«ã¯ãªã¼ãã¹ãã£ã¦ãã¿ããã§ãããã£ã±ãè¬ã®ãããããªãâ¦
ã¤ãã«ãªã¼ãã¹ãå¦æ¹ããã¾ãããåºãã¨ã¯æããªãã£ãã»ã»ã»ã ãªã¼ãã¹ã¯æãã¤ã¡ã¼ã¸ãããã ä»ã¾ã§é£²ãã§ãæãã¤å¤ã¨çµã¿åããããã¨ã§å¹æãå¢å¼·ãããã¿ãããªèª¬æãããã¾ããã 200mg/dayããéå§ã§ãã ããã§ä¸ç°ç³»ï¼SSRIï¼ãªãã¦ã ã®çµã¿åãâ¦
主治å»ã¯ãã¤ç ã ã£ã¦è¨ã£ã¦ãã®ç åã§è¨ºææ¸ãããã£ã¦ãã®ã§ãããç£æ¥å»ã¯ããæã£ã¦ãªãæ°ããã¾ãã ååä¸ã®ç æ°ãè¬ã®å¯ä½ç¨ã ã£ã¦å¼·ç¡¬ã«ä¸»å¼µãããã»ã» ç ãã®ã¯ã³ã¼ãã¼ã¨ã飲ãã§ã¡ãã£ã¨ããã°ã£ã¦ã¿ã¦ã ã¨ãè¨ããã¾ããã 飲ãã§ãããªããªãâ¦
ãã¤ç ã¨è¨ºæããã¦ããäºå¹´å¼±ãããçµã¡ã¾ããã ã ããããããªã£ãã¨æãã®ã§ããããã£ããæãã¾ã æ®ã£ã¦ã¾ãã ç¡çããããªã¨ä¸»æ²»å»ã«è¨ããã¦ããã®ã§ãç¡çããªãç¯å²ã§ä»äºãã¦ã¾ãã ä¸å¸ãé æ ®ãã¦ä»äºéã調æ´ãã¦ããã¦ãã®ã§ããªãã¨ããã£ã¦â¦
ãã¤ã¹ãªã¼ã¨ãã®ç å¤ã¯äºé±éã¾ã§ããåºããªããããã§ããã ã¡ããã©å¦ä¼ãããçä¼ã¿ã¨éãªãã®ã§ä¸é±éå¾ããå»è ã«ããããªãã®ã§ãã ããããã¤ã¹ãªã¼5mgÃ2ã§äºé±éååºãã®ã§5mgãã¤é£²ãã§ãã ããã£ã¦è¨ãããã ãã®åãããã¹ãå¢éã«ã ãªã¹ãâ¦
ç´ä¸å¹´ã¶ãã§ããã ç ããªãã®ã§ããã¤ã¹ãªã¼ã¨ããã¹ã追å ã«ãªãã¾ããã å¯ãåã« ãã¤ã¹ãªã¼10mg ããã¹2mgã§ãããã¤ã¹ãªã¼ã¯è¨æ¶ãé£ã¶ã®ã§é¢ç½ãã§ããã å¯ãåã«ãããã¨ããã£ã±ãè¦ãã¦ãªããã§ãã å¯ãåã«æ¬èªãã§ãããã£ã±ãè¦ãã¦ãªãã â¦
ãã°ããæ¸ãã¦ãã¾ããã§ãããã ãã°ããè¦ãªãéã«ããªãå¤ãã£ã¦ã¾ããç·¨éç»é¢ã»ã»ããã¤ã§å»è ããè¬ãå¦æ¹ããã¦ãã¾ãã ãã¾é£²ãã§ãè¬ã¯ããã®éãã ã½ã©ããã¯ã¹ 0.8mg/day ã¢ã¢ããµã³ 150mg/day åããï¼ãã¤ã®ï¼ç´ å ã¯ãã£ãã®ã§ããããããâ¦